Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.59 |
| ▸ | NPC1 | O15118 | 13/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125150 | 1.00 | RAB9A (0.59) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL28162213 | 0.86 | PTGS2 (0.51) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| 2-Phenylquinoline SCHEMBL18143576 | 0.78 | RAB9A (0.59) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL12112870 | 0.78 | RAB9A (0.80) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL707757 | 0.76 | PDGFRB (0.58) | RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL28184297 | 0.76 | BACE1 (0.49) | RAB9ANPC1KMT2AMAPTPDGFRB | |
| 2-Phenylquinoline SCHEMBL44999 | 0.76 | RAB9A (0.73) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| 2-Phenylquinoline SCHEMBL29399739 | 0.76 | RAB9A (0.73) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL170196 | 0.75 | RAB9A (0.64) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL29374931 | 0.75 | RAB9A (0.64) | RAB9ANPC1ARCYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448876-B | Asymmetric transfer hydrogenation method for quinoline | 哈尔滨工业大学（深圳） | 2023-10-31 | — | — | CN | disclosed |
| CN-115448876-A | Asymmetric transfer hydrogenation method for quinoline | 哈尔滨工业大学（深圳） | 2022-12-09 | — | — | CN | disclosed |
| CN-109071446-B | Organic reaction in aqueous solution in the presence of hydroxyalkyl (alkyl) cellulose or alkylcellulose | 艾伯维德国有限责任两合公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-113121427-B | Quinoline derivative and preparation method and application thereof | 广东工业大学 | 2022-04-01 | — | — | CN | disclosed |
| CN-113929623-A | Synthesis method of 2-arylquinoline compound | 温州医科大学附属口腔医院 | 2022-01-14 | — | — | CN | disclosed |
| CN-113121427-A | Quinoline derivative and preparation method and application thereof | 广东工业大学 | 2021-07-16 | — | — | CN | disclosed |
| CN-110467568-A | A kind of synthetic method of aryl quinoline derivatives | UNIV WENZHOU | 2019-11-19 | — | — | CN | disclosed |
| WO-2015040424-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-03-26 | — | — | WO | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | RAB9A 4723/4885NPC1 19/4885AR 49/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | RAB9A 4606/4885NPC1 48/4885AR 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.